Schuster, S. R., Girnius, S., Kaedbey, R., Ochoa, P., Pour, L., Calloch, R. L., Slørdahl, T. S., Becker, A. D., Hong, F., Hoyle, M., Yver, A., Finn, G., Chalopin, T. (2025). MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps7568